Compare ACDC & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | MGTX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 909.1M |
| IPO Year | 2021 | 2018 |
| Metric | ACDC | MGTX |
|---|---|---|
| Price | $6.82 | $9.19 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.50 | ★ $24.57 |
| AVG Volume (30 Days) | ★ 1.4M | 715.9K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,941,800,000.00 | $81,391,000.00 |
| Revenue This Year | N/A | $141.38 |
| Revenue Next Year | $11.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $3.08 | $6.21 |
| 52 Week High | $10.70 | $11.85 |
| Indicator | ACDC | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 46.27 |
| Support Level | $5.82 | $8.82 |
| Resistance Level | $7.85 | $9.65 |
| Average True Range (ATR) | 0.60 | 0.49 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 39.96 | 17.17 |
ProFrac Holding Corp is a technology-focused, vertically integrated energy services company providing hydraulic fracturing, proppant production, completion services, and related products, including distributed power generation, to upstream oil and natural gas companies in the United States. The Company operates through four segments: Stimulation Services, Proppant Production, Manufacturing, and Flotek. The Stimulation Services segment, which generates maximum revenue, provides hydraulic fracturing services using mobile units and auxiliary equipment. The Proppant Production segment supplies proppant, the Manufacturing segment sells engineered products such as pumps, valves, and piping, and Flotek is a chemistry and data technology company serving the E&P industry.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.